These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7002563)

  • 1. Noninvasive assessment of the cardiovascular effects of prostacyclin (PGI2) in man.
    Warrington SJ; Smith PR; O'Grady J
    Eur J Cardiol; 1980; 12(2):73-80. PubMed ID: 7002563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
    Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.
    Hassan S; Pickles H; Fish A; Burke C; Warrington S; O'Grady J
    Br J Clin Pharmacol; 1982 Sep; 14(3):369-77. PubMed ID: 6127095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and electrophysiological analysis of a selective vasodilatory prostacyclin analogue, 5-nitro-PGI1.
    Kecskeméti V; Stadler I; Körmöczy P
    Biomed Biochim Acta; 1984; 43(8-9):S287-90. PubMed ID: 6440542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole.
    Pickles H; Fish A; Hassan S; Burke C; Warrington S; O'Grady J
    Clin Pharmacol Ther; 1983 Feb; 33(2):178-82. PubMed ID: 6337004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation in dogs.
    Fletcher JR; Ramwell PW
    Circ Shock; 1980; 7(3):299-308. PubMed ID: 7004660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular actions of prostacyclin (PGI2) in the cat.
    Lippton HL; Paustian PW; Mellion BT; Nelson PK; Feigen LP; Chapnick BM; Hyman AL; Kadowitz PJ
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):121-30. PubMed ID: 393193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of prostacyclin on some hemodynamic parameters in dogs.
    Filczewski M; Oledzka K
    Pol J Pharmacol Pharm; 1981; 33(5):491-8. PubMed ID: 7038645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemodynamics and changes in compliance of the extra-thoracic capacity system following administration of prostacyclin (PGI2)].
    Kramer M; Schleussner E; Schmidt A; Heinrich D; Walter P; Hempelmann G
    Herz; 1984 Apr; 9(2):102-9. PubMed ID: 6370814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic and metabolic effects of prostacyclin after coronary bypass surgery.
    Chelly J; Fabiani JN; Chahine R; Tricot AM; Carpentier A; Passelecq J; Dubost C
    Circulation; 1982 Aug; 66(2 Pt 2):I45-9. PubMed ID: 7044613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2).
    Orchard MA; Ritter JM; Shepherd GL; Lewis PJ
    Br J Clin Pharmacol; 1983 May; 15(5):509-11. PubMed ID: 6344895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoprostenol (prostacyclin,PGI2) increases apparent liver blood flow in man.
    Hassan S; Pickles H
    Prostaglandins Leukot Med; 1983 Apr; 10(4):449-54. PubMed ID: 6344102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
    Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiac effects of prostacyclin infusion].
    Camici M
    Minerva Med; 1990 Oct; 81(10):697-9. PubMed ID: 2234464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs.
    Starnes VA; Primm RK; Woosley RL; Oates JA; Hammon JW
    J Cardiovasc Pharmacol; 1982; 4(5):765-9. PubMed ID: 6182407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostacyclin effect on cardiovascular system in man evaluated by echocardiography.
    Triulzi MO; Cirino D; Gentile F; Balice G; Aguggini G; Maggi GC
    Prostaglandins Med; 1981 Dec; 7(6):501-10. PubMed ID: 7034023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation].
    Fabiani JN; Bunting S; Terrier E; O'Grady J; Fontaine B; Prigent C; Carpentier A; Vane J; Dubost C
    Arch Mal Coeur Vaiss; 1982 Mar; 75(3):241-8. PubMed ID: 6807240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N; Lundin S; Ricksten SE
    J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some cardiovascular properties of prostacyclin (PGI2) which are not shared by PGE2.
    Dusting GJ; Vane JR
    Circ Res; 1980 Jun; 46(6 Pt 2):I183-7. PubMed ID: 6991150
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.
    Rongen GA; Smits P; Ver Donck K; Willemsen JJ; De Abreu RA; Van Belle H; Thien T
    J Clin Invest; 1995 Feb; 95(2):658-68. PubMed ID: 7860749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.